Navigation Links
ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results
Date:11/3/2008

.

"Forcefield is an enabling technology insofar as the biocompatible interface that we create between a device and the bloodstream is the result of controlling the manner by which a person's blood first interacts with a device. The result is a natural solution and genuinely biocompatible interface between the device and bloodstream. The magnitude of this achievement is one of a kind and we predict will be disruptive in the future to the implantable device marketplace," said Michael Dale, President and CEO. "The elimination of long term anti-coagulation medication would provide physicians greater therapy options in the selection of device type and most importantly better therapy for their patients."

Images of ATS Forcefield study results are available for viewing on atsmedical.com using the following link: http://phx.corporate-ir.net/phoenix.zhtml?c=89111&p=irol-presentations

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 160,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-l
'/>"/>

SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 High ... and apply the most complete climate and Earth ... demanding climate change issues. , Eight national laboratories, ... with the National Center for Atmospheric Research, four ... new effort. Other participating national laboratories include Argonne, ...
(Date:8/20/2014)... -- PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in New York.  Ingo Bank , ... making a presentation on PAREXEL and discussing business developments ... A live webcast of the discussion will ... at www.PAREXEL.com in the Upcoming Events portion ...
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
Breaking Biology Technology:Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... aTyr Pharma, the physiocrine therapeutics company, today announced ... by Domain Associates.  Domain joins existing venture investors ... also participated in the financing.  Proceeds will be ... pipeline and advance physiocrine drug candidates into clinical ...
... announced that it has successfully modified yeast to be ... encountered in the bioproduction of fuel ethanol. In doing ... more ethanol. "We are very pleased ... developing a 2nd generation with yet better commercial performance ...
... ITHACA, N.Y. The human hand is an amazing ... but for a robot, this "gripping" mechanism is a vexing ... of Chicago and iRobot have bypassed traditional designs based around ... using everyday ground coffee and a latex party balloon. ...
Cached Biology Technology:aTyr Pharma Secures $23M Financing From Top Tier Venture Investor 2iDiverse Develops Stress Resistant Yeast for Producing Fuel Ethanol 2Robotic gripper runs on coffee ... and balloons 2
(Date:8/21/2014)... Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication ... today that its shares of common stock and the ... its proposed underwritten public offering of common stock and ... Capital Market, subject to closing of its proposed underwritten ... will trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... seem easy to ignore, but they are the ultimate ... upon. Humans are increasingly dependent on algae, too, to ... sink it to the bottom of the ocean. Now, ... experiments, researchers have evidence showing that viruses infecting those ... blooms, even when all else stays essentially the same, ...
(Date:8/21/2014)... MELBOURNE, Fla. , Aug. 21, 2014 ...  announced that it has agreed to a ... Orlando,s fastest growing Certified ... make  Gabriel Health Institute  an exclusive member ... a result, Binary Biometrics will improve its ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Viruses take down massive algal blooms, with big implications for climate 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3
... underfunding health: so what kind of new development paradigm will ... and where will sexual and reproductive health and rights (SRHR) ... latest themed issue of Reproductive Health Matters explore ... at the global policy level, and the evolution of the ...
... 9, 2013) A new study shows that high school ... closer to sea-level, a phenomenon attributed to physiological changes in ... skull. "This is the first time any research has ... professor of epidemiology at the Colorado School of Public Health ...
... , Dec. 9, 2013 Today, the country,s ... a Series D extension of $15 million in new ... its venture capital arm, Qualcomm Ventures, brings Practice Fusion,s ... raised to date at $149 million. The round was ...
Cached Biology News:Reproductive Health Matters announces publication of its latest themed issue: New development paradigm 2Study shows first link between altitude and concussion 2Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 2Practice Fusion Raises Additional $15M to Close Year of Exponential Platform Growth 3
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Catalase (Control)...
Biology Products: